MNMD Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Mind Medicine's net margin of 12.11%. Mind Medicine's return on equity of -- beat Electromed's return on equity of 15.91%.

Mind Medicine has a consensus price target of $24.50, signalling upside risk potential of 279.85%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 50.1%. Given that Mind Medicine has higher upside potential than Electromed, analysts believe Mind Medicine is more attractive than Electromed.

Mind Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Mind Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mind Medicine pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Mind Medicine quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Mind Medicine's net income of -$34.7M is lower than Electromed's net income of $2M. Notably, Mind Medicine's price-to-earnings ratio is -- while Electromed's PE ratio is 32.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mind Medicine is -- versus 3.70x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -- compared to Mind Medicine's net margin of -2.16%. Mind Medicine's return on equity of -- beat Myomo's return on equity of -48.64%.

Mind Medicine has a consensus price target of $24.50, signalling upside risk potential of 279.85%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 74.2%. Given that Mind Medicine has higher upside potential than Myomo, analysts believe Mind Medicine is more attractive than Myomo.

Mind Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Myomo has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.902%.

Mind Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mind Medicine pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Mind Medicine quarterly revenues are --, which are smaller than Myomo quarterly revenues of $12.1M. Mind Medicine's net income of -$34.7M is lower than Myomo's net income of -$260.1K. Notably, Mind Medicine's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mind Medicine is -- versus 6.16x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to Mind Medicine's net margin of -1226.82%. Mind Medicine's return on equity of -- beat VolitionRX's return on equity of --.

Mind Medicine has a consensus price target of $24.50, signalling upside risk potential of 279.85%. On the other hand VolitionRX has an analysts' consensus of $3.37 which suggests that it could grow by 518.96%. Given that VolitionRX has higher upside potential than Mind Medicine, analysts believe VolitionRX is more attractive than Mind Medicine.

Mind Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.182%.

Mind Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mind Medicine pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Mind Medicine quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $474.5K. Mind Medicine's net income of -$34.7M is lower than VolitionRX's net income of -$5.8M. Notably, Mind Medicine's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mind Medicine is -- versus 35.18x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Mind Medicine's net margin of -10.04%. Mind Medicine's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

Mind Medicine has a consensus price target of $24.50, signalling upside risk potential of 279.85%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 264.58%. Given that Mind Medicine has higher upside potential than Xtant Medical Holdings, analysts believe Mind Medicine is more attractive than Xtant Medical Holdings.

Mind Medicine has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.747%.

Mind Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mind Medicine pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Mind Medicine quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Mind Medicine's net income of -$34.7M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Mind Medicine's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mind Medicine is -- versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.